Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) wishes to advise of its progress in licensing its core intellectual property pertaining to non-coding DNA.
With the regulatory process well underway in China, Helicon (ASX: HCG) has put the ReCell(R) pre-marketing program into gear with a number of activities over the last few months.
The Directors of Solagran Limited (ASX: SLA) are pleased to announce that the Russian Agency for Patents and Trademarks has accepted a patent application submitted by Solagran covering the use of Bioeffective(r) A in the treatment of Helicobacter pylori infection. If awarded, the priority date for this patent will be 26 December, 2007.
Australian Biotech Solagran Limited (ASX: SLA) today announced it had been awarded the world's first patents protecting the use of plant polyprenols in the treatment of conditions involving physical, psychological and neurological degeneration.
Australian Biotech Solagran Limited (ASX: SLA) announced at its AGM today that it was on track to commence commercial production of its drug Ropren in January 2008.
Universal Biosensors Inc. (ASX: UBI) - Operational Update - Mr Mark Morrisson, CEO; Universal Biosensors Inc. (ASX: UBI) present the following audio webcast regarding "Operational Update". You may also download this audio webcast to your computer or portable audio player.
The Directors of Solagran Limited (ASX: SLA) are pleased to announce the achievement of two important milestones in the ongoing development of its Bioeffective-R production facilities in Tomsk.
